PharmaFocus Today – Page 139 – media

Innovent Biologics’ PD-1 bispecific antibody is again granted FDA Fast Track Qualification

On February 17, Innovent Biologics announced that its PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 was granted Fast Track Qualification (FTD) by the US FDA, with the proposed indication being locally advanced or metastatic squamous non-small cell lung cancer that has progressed after anti-PD-(L)1 immune checkpoint inhibitors and platinum-containing chemotherapy. This is the second time that IBI363 has been granted FDA Fast Track Qualification after melanoma. According to the data, IBI363 is the world’s first PD-1/IL-2 bispecific fusion protein independently developed by Innovent Biologics, which has the functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. IBI363 has shown positive efficacy and safety signals in a variety of advanced solid tumors. Innovent Biologics is currently conducting Phase 1/2 clinical studies of IBI363 in China and the United States. https://finance.eastmoney.com/a/202502183321598760.html
- Source: drugdu
- 284
- February 18, 2025
AI medical concept continues to be strong, Meinian Health has 5 boards in 7 days

On February 17, AI medical concept stocks continued to be hot in the capital market. Meinian Health has 5 boards in 7 days, Anping has 20CM for two consecutive days, Saili Medical has 5 boards in 10 days, Jiahe Meikang, Xin Ganjiang, Sichuang Yihui, and Chaoyan shares have risen by more than 10%. Some popular concept stocks have also successively issued announcements on abnormal stock trading fluctuations. For example, Meinian Health announced on February 16 that the company’s current business situation is normal, and there has been no major changes in the internal and external business environment. After verification, the company and the actual controller have no major matters that should be disclosed but have not been disclosed or major matters in the planning stage. Anping issued an announcement on February 17, saying that the company has recently noticed that many media reported that Huawei Technologies Co., Ltd. will build ...
- Source: drugdu
- 238
- February 18, 2025
The epidemic of acute respiratory infectious diseases in my country continues to decline

According to CCTV News on February 17, the National Health Commission held a press conference to introduce the seasonal solar terms and health-related situations. Media reports that influenza viruses are still prevalent in some countries and regions recently. What is the current monitoring situation of respiratory infectious diseases such as influenza in my country? Peng Zhibin, a researcher at the Chinese Center for Disease Control and Prevention, introduced that the current monitoring results indicate that the epidemic of acute respiratory infectious diseases in my country continues to decline. Among them, influenza virus is the main pathogen causing recent acute respiratory infections. It is still in the seasonal epidemic period, but the overall epidemic intensity is on a downward trend; there are differences in the level of influenza activity in the north and south. In the sixth week, the south was higher than the north. The positive rates of Mycoplasma pneumoniae ...
- Source: drugdu
- 253
- February 18, 2025
How AI Procurement Can Boost Supply Chain Efficiency by 50% in the Pharmaceutical Industry? Drugdu AI is Exploring the Future!

Traditional procurement faces high costs, lack of supply chain transparency, and complex compliance processes. Drugdu AI is developing intelligent procurement solutions to make pharmaceutical B2B purchasing more efficient and smarter! What is Drugdu AI? Drugdu AI is a leading B2B pharmaceutical procurement platform that has built a global database of pharmaceutical suppliers. By leveraging AI-driven decision-making and data-powered supply chain optimization, Drugdu AI aims to enhance matching accuracy and reduce procurement risks. Drugdu AI’s Core Capabilities 1. Global B2B Pharmaceutical Trading Platform Drugdu.com has built a digital procurement ecosystem covering pharmaceuticals, medical devices, and pharmaceutical raw materials. It seamlessly connects manufacturers, suppliers, and buyers worldwide, facilitating efficient cross-border transactions. 2. Intelligent Supply Chain Solutions The platform provides end-to-end services, including precise supplier matching, real-time price transparency, international logistics optimization, and inventory management—significantly shortening procurement cycles and reducing transaction costs. 3. Integrated Compliance & Certification Support Drugdu AI integrates FDA, GMP, ...
- Source: drugdu
- 691
- February 18, 2025
AI DeepSeek Drugdu AI intelligent procurement solutions pharma
Beilu Pharmaceutical’s compound polyethylene glycol electrolyte powder (III) has been approved for registration

February 14, 2025 10:26 Author: Chen Xi Source: Shanghai Securities Journal · China Securities Network On the evening of February 13th, Beilu Pharmaceutical announced that it had successfully received the Drug Registration Certificate for Compound Polyethylene Glycol Electrolyte Powder (III) approved and issued by the National Medical Products Administration. This drug belongs to Class 4 of chemical drugs and is considered to have passed the quality and efficacy consistency evaluation of generic drugs. Compound polyethylene glycol electrolyte powder, as a commonly used intestinal cleansing and penetrating laxative in clinical practice, has a broad market demand. According to data from MineNet, in 2023, its terminal sales in public medical institutions in China exceeded 1.3 billion yuan, and compound polyethylene glycol electrolyte powder (III) has been included in the tenth batch of national centralized drug procurement. This approval further enriches the product pipeline of Beilu Pharmaceutical in the field of digestive system ...
- Source: drugdu
- 580
- February 17, 2025
The 10th Batch of Centralized Procurement Promotes Continuous Improvement in Demand for Borosilicate Pharmaceutical Glass

Guolian Minsheng Securities has released a special research report on the building materials industry. The tenth batch of national drug procurement bidding will be held in December 2024, involving 62 drug varieties and 263 product specifications, all of which are drugs that have passed the patent period, produced by multiple enterprises, and have sufficient competition, covering key areas such as hypertension and tumors. 385 products from 234 enterprises have obtained the qualification for selection, and all selected drugs have passed the evaluation of quality and efficacy consistency. The tenth batch of centralized procurement is expected to commence in April 2025. The centralized procurement of up to ten batches is the core driving force for the increase in boron silicon permeability in medicinal glass The consumption structure of drugs in China is mainly dominated by generic drugs, and in the past, generic drugs have dominated through centralized procurement. In fact, the ...
- Source: drugdu
- 236
- February 17, 2025
Yongji shares set up overseas subsidiaries to expand overseas controlled drug business

On the evening of February 13, an announcement was issued stating that in accordance with the company’s strategic planning and business development needs, in order to expand the controlled drug business, the company’s second-level wholly-owned subsidiary Y Cannabis Holdings Pty Ltd established a wholly-owned subsidiary Yongji Health in New Zealand. The announcement stated that the establishment of a wholly-owned subsidiary is in line with the company’s own strategic layout and business development needs, is conducive to the expansion of overseas controlled drug business, further expands the business layout, and has a positive effect on the company’s development and efficiency improvement. In the process of expanding the overseas controlled drug business, the subsidiary may face uncertainties in macroeconomics, industry policy changes, market changes, business management, exchange rate changes, etc. The company will closely monitor the subsequent progress of the subsidiary, actively prevent and respond to various risks that may be faced, ...
- Source: drugdu
- 242
- February 17, 2025
Anke Bio will become a cornerstone investor

On February 11, 2025, Anko Bio (stock code: 300009.SZ), a well-known A-share listed company, issued an announcement, announcing that it will use its own funds of no more than US$31 million (including brokerage commissions and related fees such as levies) to participate in the subscription of Weisheng Pharmaceutical’s initial public offering of shares on the Hong Kong stock market. The announcement clearly stated: “This investment is based on Anko Bio’s strategic development plan and aims to promote in-depth strategic cooperation between the two parties and further enhance Anko Bio’s risk resistance, core competitiveness and capital market influence.” On the evening of February 9, information from the Hong Kong Stock Exchange showed that Weisheng Pharmaceuticals had officially passed the Hong Kong Stock Exchange hearing. As of now, the company has established a product pipeline consisting of three candidate drugs, including lonapegsomatropin, navepegritide, and palopegteriparatide, which are used to treat childhood growth ...
- Source: drugdu
- 360
- February 17, 2025
The first domestically produced PD-1 for head and neck squamous cell carcinoma, Sinocell’s “Fenolimab” was approved for marketing

On February 8, according to the official website of NMPA, the fenolimab injection (trade name: Anyouping) submitted by Sinocell Engineering Co., Ltd. was approved for marketing. Indications: This product is used in combination with platinum-containing chemotherapy for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. Fenolimab is a recombinant humanized anti-PD-1 IgG4 monoclonal antibody injection independently developed by Sinocell. It can block the binding of PD-1 to its ligand, increase the supply of T cells and inflammatory cytokines in the tumor site, reduce the proportion of regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment, change the tumor microenvironment, restore and enhance the immune killing function of T cells, and thus inhibit tumor growth. According to Yaozhi data, as of now, 12 PD-1 monoclonal antibodies have been approved for marketing in China, including 2 imported drugs and 10 domestic drugs. In terms of ...
- Source: drugdu
- 379
- February 17, 2025
Huiyu Pharmaceutical’s magnificent transformation

Among the pharmaceutical stocks that have released their 2024 annual performance forecasts, Huiyu Pharmaceutical’s performance is impressive enough. In 2024, it is expected to achieve a net profit of 300 million yuan to 360 million yuan, a year-on-year increase of 114.61%-157.54%. Net profit after deducting non-recurring gains and losses is expected to be between 95 million yuan and 110 million yuan, a year-on-year increase of 43.92%-66.64%. Huiyu Pharmaceutical was once known as the “lucky guy” of centralized procurement, having stood out in centralized procurement and won the main domestic market share of pemetrexed disodium. However, with the increasingly fierce market competition, its share has been gradually eroded. However, under the guidance of innovation and internationalization strategies, performance has gradually recovered, and the innovative drug business has also been put on the right track and revitalized again. With 40 high-end generic drugs in hand, in 2017 and 2018, Huiyu Pharmaceutical’s core ...
- Source: drugdu
- 324
- February 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.